COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date
Revelation Biosciences cancels Special Meeting of Stockholders due to technical difficulty, sets new date. Focus on rebalancing inflammation with Gemini formulation -
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: PSI expects higher one-time expenses in fiscal year 2025
PSI Software SE expects higher one-time expenses in fiscal year 2025 due to transaction costs related to an investment agreement with Warburg Pincus. Company anticipates growth in order intake and sales for the year -
COMMUNIQUÉ DE PRESSE
Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive
NanoViricides, Inc. announced progress in antiviral research with their drug NV-387 showing potent activity against Measles virus. Clinical trials have shown safety and effectiveness, positioning for emergency use -
-
COMMUNIQUÉ DE PRESSE
DEBRA Research Invests in Eliksa Therapeutics to Advance ELK-003, a Biological Eye Drop for Epidermolysis Bullosa-Related Ocular Complications
DEBRA Research invests in Eliksa Therapeutics to advance ELK-003, a biological eye drop for Epidermolysis Bullosa-related ocular complications, supported by a syndicate of mission-driven organizations -
COMMUNIQUÉ DE PRESSE
GameSquare Announces Strategic Partnership with Katana
GameSquare Holdings announces strategic partnership with Katana, a DeFi blockchain, to deploy Ethereum holdings in unique yield-generating infrastructure, in collaboration with Dialectic, 1OF1, Goff Capital, and Robert Leshner for sustainable onchain returns -
COMMUNIQUÉ DE PRESSE
Goldstrom Partners with SMX to Deliver End-to-End Traceability and Circularity in Precious Metals
SMX (Security Matters) PLC partners with Goldstrom Advisory FZCO to enhance traceability within the precious-metals industry through molecular-marker technology and blockchain-backed digital product passports -
-
COMMUNIQUÉ DE PRESSE
Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome
Medicus Pharma collaborates with the Gorlin Syndrome Alliance to provide compassionate access to SKINJECT™, a novel therapy for Gorlin Syndrome patients. The initiative aims to collect real-world data and integrate patient insights for future development
